ArticleBMC biotechnology2026
Enhanced production of Nattokinase by Bacillus aryabhattai RP6 isolated from fermented Brassica oleracea.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNattokinase (NK) in recent times has been identified as an important enzyme for its health benefits and its application in cardiovascular diseases (CVD). NK is known for its thrombolytic activity and has been actively used its low cost of production. The research study aims to enhance the Nattokinase production from fermented Brassica oleracea.
resultsSeven different fermented and non-fermented food sources were screened for fibrinolytic protease-producing bacteria. Out of 12 bacterial isolates, 7 were identified as protease producers. However, the strain RP6 isolated from fermented Brassica oleracea exhibited higher fibrinolytic activity. Morphological, biochemical, and molecular characterization revealed RP6 as Bacillus aryabhattai. Optimization studies showed maximum NK production when glycerol and ammonium chloride were used as carbon and nitrogen sources, respectively, at pH 10, inoculum size of 2%, and incubation at 37 °C. The purified enzyme, with an apparent molecular mass of 29 kDa, demonstrated maximum fibrinolytic activity of 88.87% after 3 h.
conclusionThe study identifies Bacillus aryabhattai RP6 as a potent NK-producing strain. Its high yield and strong fibrinolytic activity highlight its potential for industrial-scale NK production and possible application in cardiovascular therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.